<SEC-DOCUMENT>0000950157-25-000596.txt : 20250730
<SEC-HEADER>0000950157-25-000596.hdr.sgml : 20250730
<ACCEPTANCE-DATETIME>20250730175613
ACCESSION NUMBER:		0000950157-25-000596
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250730
DATE AS OF CHANGE:		20250730

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sage Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001597553
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88275
		FILM NUMBER:		251168429

	BUSINESS ADDRESS:	
		STREET 1:		55 CAMBRIDGE PARKWAY
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-299-8380

	MAIL ADDRESS:	
		STREET 1:		55 CAMBRIDGE PARKWAY
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13D/A</submissionType>
<previousAccessionNumber>0000950157-25-000586</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0000875045</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>2</amendmentNo>
<securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
<dateOfEvent>07/30/2025</dateOfEvent>
<previouslyFiledFlag>true</previouslyFiledFlag>
<issuerInfo>
<issuerCIK>0001597553</issuerCIK>
<issuerCUSIP>78667J108</issuerCUSIP>
<issuerName>Sage Therapeutics, Inc.</issuerName>
<address>
<com:street1>55 Cambridge Parkway</com:street1>
<com:city>Cambridge</com:city>
<com:stateOrCountry>MA</com:stateOrCountry>
<com:zipCode>02142</com:zipCode>
</address>
</issuerInfo>
<authorizedPersons>
<notificationInfo>
<personName>Wendell Taylor, Secretary</personName>
<personPhoneNum>(617) 679-2000</personPhoneNum>
<personAddress>
<com:street1>Biogen Inc.</com:street1>
<com:street2>225 Binney Street</com:street2>
<com:city>Cambridge</com:city>
<com:stateOrCountry>MA</com:stateOrCountry>
<com:zipCode>02142</com:zipCode>
</personAddress>
</notificationInfo>
</authorizedPersons>
</coverPageHeader>
<reportingPersons>
<reportingPersonInfo>
<reportingPersonCIK>0000875045</reportingPersonCIK>
<reportingPersonName>Biogen Inc.</reportingPersonName>
<fundType>OO</fundType>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
<aggregateAmountOwned>0</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>0</percentOfClass>
<typeOfReportingPerson>CO</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonNoCIK>Y</reportingPersonNoCIK>
<reportingPersonName>Biogen MA Inc.</reportingPersonName>
<fundType>OO</fundType>
<citizenshipOrOrganization>MA</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
<aggregateAmountOwned>0</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>0</percentOfClass>
<typeOfReportingPerson>CO</typeOfReportingPerson>
</reportingPersonInfo>
</reportingPersons>
<items1To7>
<item1>
<securityTitle>Common Stock, par value $0.0001 per share</securityTitle>
<issuerName>Sage Therapeutics, Inc.</issuerName>
<issuerPrincipalAddress>
<com:street1>55 Cambridge Parkway</com:street1>
<com:city>Cambridge</com:city>
<com:stateOrCountry>MA</com:stateOrCountry>
<com:zipCode>02142</com:zipCode>
</issuerPrincipalAddress>
<commentText>The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned ("Amendment No. 2") on January 10, 2024, as amended by Amendment No. 1 on July 21, 2025. This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.</commentText>
</item1>
<item5>
<percentageOfClassSecurities>Item 5 is hereby amended and restated in its entirety as follows:&#13;
&#13;
As of July 28, 2025,  the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons was 6,241,473.00 shares, representing 9.941% of the 62,784,397 issued and outstanding shares of Common Stock of the Issuer as of July 23, 2025 (as disclosed in the Issuer's most recent quarterly report on Form 10-Q filed on July 30, 2025). &#13;
&#13;
On July 29, 2025, the Reporting Persons sold all of their shares of Common Stock at a price per share of $8.53 in a block trade.&#13;
&#13;
As of the date of this filing, the Reporting Persons beneficially own no shares of Common Stock, representing 0.00% of the issued and outstanding shares of Common Stock.  As of the date of this filing, the Reporting Persons have no powers to vote, or to direct the vote of, or to dispose, or to direct the disposition of, shares of Common Stock.</percentageOfClassSecurities>
<numberOfShares>Item 5(a) of this Schedule 13D is incorporated by reference into this Item 5(b).</numberOfShares>
<transactionDesc>Item 5(a) of this Schedule 13D is incorporated by reference into this Item 5(c).</transactionDesc>
<listOfShareholders>Not applicable.</listOfShareholders>
<date5PercentOwnership>On July 29, 2025, the Reporting Persons ceased to be the beneficial owners of more than five percent of Common Stock.</date5PercentOwnership>
</item5>
</items1To7>
<signatureInfo>
<signaturePerson>
<signatureReportingPerson>Biogen Inc.</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Michael Dambach</signature>
<title>Michael Dambach / Treasurer</title>
<date>07/30/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Biogen MA Inc.</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Michael Dambach</signature>
<title>Michael Dambach / Treasurer</title>
<date>07/30/2025</date>
</signatureDetails>
</signaturePerson>
</signatureInfo>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
